Glaxo-smith-kline-presentation.
Upcoming SlideShare
Loading in...5
×
 

Glaxo-smith-kline-presentation.

on

  • 7,532 views

 

Statistics

Views

Total Views
7,532
Views on SlideShare
7,532
Embed Views
0

Actions

Likes
1
Downloads
358
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

 Glaxo-smith-kline-presentation. Glaxo-smith-kline-presentation. Presentation Transcript

  • Glaxo Smith Kline
  • GSK’S Introduction
    GlaxoSmithKline often abbreviated to GSK, is a global
    pharmaceutical, biologics, vaccines and consumer
    healthcare company headquartered in London, United
    Kingdom.
  • GSK’S Introduction
    It is world’s third largest pharmaceutical company measured by revenues ( after Johnson and Johnson and Pfizer.
    It has a portfolio of products for major disease areas including asthma, cancer, virus control, infections, mental health, diabetes and digestive conditions.
  • History
    • GlaxoSmithKline plc is a public limited company incorporated on 6th December 1999 under English law. Its shares are listed on the London Stock Exchange and the New York Stock Exchange.
    • On 27th December 2000 the company acquired Glaxo Wellcome plc and SmithKline Beecham plc, both English public limited companies, by way of a scheme of arrangement for the merger of the two companies.
  • History
    GSK and its subsidiary and associated undertakings constitute a major global healthcare group engaged in the creation, discovery, development, manufacture and marketing of pharmaceutical and consumer health-related products.
    GSK has its corporate head office in London and has its US headquarters in Research Triangle Park, North Carolina, with operations in some 120 countries, and products sold in over
    150 countries.
  • Chairman:
    Sir Christopher Gent
    Chief Executive Officer:
    Andrew Witty
  • GSK’s Mission
    GSK MISSION
    GROW
    MISSION
    SIMPLYFY
    DELIVER
  • GSK’S Mission
    • Grow a diversified global business – We are diversifying our business to create a more balanced product portfolio and move away from a reliance on traditional ‘white pill/western markets’. We are investing in key growth areas such as Emerging Markets, Japan, Vaccines and our Consumer Healthcare business.
    .
  • GSK’S Mission
    • Deliver more products of value – We aim to sustain an
    industry-leading pipeline of products, ensuring that they
    demonstrate value for healthcare providers. Our R&D
    strategy is built around focusing on the best science,
    diversifying through externalisation of research, and
    improving the returns on investment.
  • GSK’S Mission
    • Simplify the operating model – GSK is a large and complex organisation. We are transforming our operating model to reduce complexities, improve efficiency and reduce costs
  • Products
    Prescription medicines
    Vaccines
    Consumer Healthcare
  • PRESCRIPTION MEDICINES
  • ALLI-WEIGHT LOSS DRUG
  • AVANDIA-DIABETIS CONTROL
  • ROTAVIRUS VACCINE ROTARIX
  • VACCINE FOR MEASLES
  • CONSUMER HEALTHCARE PRODUCTS
  • CONSUMER HEALTHCARE PRODUCTS
  • Two other companies
    Stiefel, a GSK company— A Global Leader in Dermatology
    ViiV Healthcare —
    a global specialist HIV company established by GlaxoSmithKline and Pfizer to deliver advances in treatment and care for people
  • STIEFEL-A GSK COMPANY
  • VIIV- HEALTHCARE COMPANY
  • Turnover ( in billion pounds)
    2009 28.4
    2008 24.4
    2007 22.7
    2006 23.2
    2005 21.7
  • World market by geographic region
    value(billion pounds) % of total
    USA 187 40
    Europe 131 28
    France 25 5
    Germany 24 5
    Italy 16 3
    UK 12 3
    Rest of World 150 32
    Emerging markets 66 14
    Asia Pacific 20 4
    Japan 50 11
    Canada 11 2
  • Regional analysis
    (2009) (2008) cer% pnd%
    USA 9,180 8,894 (13) 3
    Europe 7,681 6,483 9 18
    Emerging Markets 2,973 2,290 20 30
    Asia Pacific/Japan 2,700 1,918 16 41
    Other trading‡ 1,180 796 31 48
    23,714 20,381 2 16
  • CER% represents growth at constant exchange rates.
    Pound % growth at actual exchange rates.
  • Consumer Healthcare turnover(million pounds)
    (2009) (2008) cer% pound %
    Over the counter 2,319 1935 8 20
    Medicines
    Oral healthcare 1484 1240 7 20
    Nutritional healthcare 851 796 3 7
  • Sales Trend
  • Five countries chosen
    • USA
    • JAPAN
    • GERMANY
    • SWITZERLAND
    • UK
  • COMPETITORS IN USA
    NAME OF THE COMPANY
    Johnson & Johnson
    Abbott Laboratories
    Merck & Co.
    Eli lilly
    Bristol-Myers Squibb
    TOTAL REVENUE(IN USD BILLIONS )
    61.90
    30.76
    27.43
    21.84
    18.81
  • JOHNSON &JOHNSON
  • ABBOT LABORATARIES
  • MERCK &CO.
  • ELI LILLY
  • BRISTOL-MYERS SQUIBB
  • COMPETITORS IN JAPAN
    NAME OF THE COUNTRY
    TAKEDAPHARMACEUTICAL.
    ASTELLAS PHARMA
    DAIICHI SANKYO 9
    EISAI
    CHUGAI PHARMACEUTICAL .
    TOTAL REVENUE
    (IN USD BILLIONS)
    15.6
    10.7
    9
    5.5
    2.0
  • TAKEDA PHARMACEUTICALS
  • ASTELLAS PHARMA
  • DAIICHI SANKYO
  • EISAI
  • CHUGAI PHARMACEUTICALS
  • COMPETITORS IN GERMANY
    NAME OF THE COUNTRY
    BAYER
    BOEHRINGER INGELHEIM
    MERCK kGaA
    TOTAL REVENUE
    (IN USD BILLIONS)
    22.3
    16.9
    5.17
  • BAYER
  • BOEHRINGER INGELHEIM
  • MERCK KGAA
  • COMPETITORS IN SWITZERLAND
    NAME OF THE COUNTRY
    HOFFMAN LA ROCHE
    NOVARTIS
    NYCOMED
    TOTAL REVENUE
    (IN USD BILLIONS)
    47.35
    44.27
    4.26
  • HOFFMAN LA ROCHE
  • NOVARTIS
  • NYCOMED
  • COMPETITORS IN UK
    NAMEOF THE COMPANY
    TOTAL REVENUE
    (IN USD BILLIONS)
    45.83
    32.81
    GlaxoSmithKline
    AstraZeneca
  • ASTRA ZENECA
  • SUBMITTED BY:
    ISHDEEP SINGH
    M100700019